49 results on '"Cordier, J."'
Search Results
2. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2017 update. Short-length version
- Author
-
Cottin, V., Crestani, B., Cadranel, J., Cordier, J.-F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J.-C., Dromer, C., Gomez, E., Israel-Biet, D., Jouneau, S., Kessler, R., Marquette, C.-H., Reynaud-Gaubert, M., Aguilaniu, B., Bonnet, D., Carré, P., Danel, C., Faivre, J.-B., Ferretti, G., Just, N., Lebargy, F., Philippe, B., Terrioux, P., Thivolet-Béjui, F., Trumbic, B., and Valeyre, D.
- Published
- 2017
- Full Text
- View/download PDF
3. Progress and challenges of the ITER TBM Program from the IO perspective
- Author
-
Giancarli, L.M., Barabash, V., Campbell, D.J., Chiocchio, S., Cordier, J.-J., Dammann, A., Dell’Orco, G., Elbez-Uzan, J., Fourneron, J.M., Friconneau, J.P., Gasparotto, M., Iseli, M., Jung, C.-Y., Kim, B.-Y., Lazarov, D., Levesy, B., Loughlin, M., Merola, M., Nevière, J.-C., Pascal, R., Ring, W., Schneiderova, I., Willms, S., Siarras, A., Shu, W., Snipes, J.A., and van der Laan, J.G.
- Published
- 2016
- Full Text
- View/download PDF
4. Progress in the integration of the ITER plant systems in auxiliary buildings
- Author
-
Kotamäki, M., Cordier, J.-J., Kuehn, I., Perrin, J.-L., Sweeney, S., and Villedary, B.
- Published
- 2016
- Full Text
- View/download PDF
5. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegenerʼs) or Microscopic Polyangiitis
- Author
-
Puéchal, Xavier, Pagnoux, Christian, Perrodeau, Élodie, Hamidou, Mohamed, Boffa, Jean-Jacques, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Merrien, Dominique, Smail, Amar, Delaval, Philippe, Hanrotel-Saliou, Catherine, Imbert, Bernard, Khouatra, Chahéra, Lambert, Marc, Leské, Charles, Ly, Kim H., Pertuiset, Edouard, Roblot, Pascal, Ruivard, Marc, Subra, Jean-François, Viallard, Jean-François, Terrier, Benjamin, Cohen, Pascal, Mouthon, Luc, Le Jeunne, Claire, Ravaud, Philippe, Guillevin, Loïc, Rispal, P., Baidi, N., Chrétien, O., Cevallos, R., Ducroix, J.-P., Darmaillacq, J.-G., Dubas, F., Maghakian, M.-N., Moreau, C., Dubos-Arvis, C., Frognier, R., Gobert, P., Pollini, J., Pingat, D., Janin-Manificat, L., Lafon, B., Kettaneh, A., Moiton, M., Ragnaud, J. M., Boudray, C., Raphanel, B., Renand, J.-P., Roux, M., Bonnaire, G., Guiso, A., André, J. M., Perrichot, R., Louvet, J., Artigues, N., Bienvenu, B., de Ligny, Hurault B., Le Hello, C., Letellier, P., Lobbedez, T., Ollivier, Y., Pujo, M., Ryckelynck, J.-P., Montseny, J.-J., Collet, P., Ayach, B., Dion, J.-J., Mouawad, H., Damade, R., Dupouët, L., Asgaraly, K., Depernet, B., Colin, T., Ioos, V., Rieu, V., Belmatoug, N., Foulon, L., Jebrak, G., du Coedic, L., Bachmeyer, C., Dumoulin, A., Godeau, B., Khellaf, M., Michel, M., Pastural, M., Schaeffer, A., Geffroy, M., Bielefeld, P., Fichet, D., Saraux, J.-L., Vinzio, S., Ehrlacher, P., Azria, A., Mariette, X., Tiab, M., Delansorne, D., Boullanger, N., Closs-Prophette, F., Goldstein, A., Bouscaud, L., Meunier, V., Hachulla, E., Hatron, P.-Y., Launay, D., Hottelart, C., Liozon, E., Longuet, O., Loustaud-Ratti, V., Soria, P., Vidal, E., Geffray, L., Henri, P., Landru, I., Guillemot, J.-M., Le Noach, J., Cordier, J.-F., Cottin, V., Gentil, B., Demolombe-Rague, S., Girard-Madoux, M.-H., Ninet, J., Pinède, L., Meynieux, J.-P., Serratrice, J., Xeridat, B., Bagnères, D., Roudier, J., Denis, B., Boillet, N., Geraads, A., Teyssandier, R., Degraeve, F., Le Quellec, A., Rivière, S., Rogé, C., Fauchay, J.-P., Wahl, D., Agard, C., Généreau, T., Meker, D., Bensakel, S., Vecina, F., Aubier, M., Foulon, G., Lelièvre, P., Lidove, O., Mignon, F., Meyer, O., Piperaud, M., Queffeulou, G., Vrtovsnik, F., Aouba, A., Arène, J.-P., Bérezné, A., Le Guern, V., Amoura, Z., Benveniste, O., Dimitri, D., Huong, Lê Thi D., Bergeron, A., Bourgarit, A., Farge, D., Mahr, A., Martinez, F., Séréni, D., Aslangul, E., Arnal, C., Cadranel, J., Daugas, E., Pelle, G., Rossert, J., Wislez, M., Gayraud, M., Bruet, A., Hillion, Y., Paccalin, M., Léone, J., Pennaforte, J.-L., Barbier, S., Legallicier, B., Dominique, S., Charasse, C., Coëtmeur, D., Duhamel, E., Goulias, J.-P., Bournerias, F., Gautherie, P., Schlienger, J.-L., Vidal, A., Diot, E., Diot, P., Vanhille, P., Bindi, P., and Cervantes, G.
- Published
- 2016
- Full Text
- View/download PDF
6. Severe Pulmonary Hypertension Associated with COPD: Hemodynamic Improvement with Specific Therapy
- Author
-
Girard, Anne, Jouneau, Stephane, Chabanne, Céline, Khouatra, Chahéra, Lannes, Morgane, Traclet, Julie, Turquier, Ségolène, Delaval, P., Cordier, J.-F., and Cottin, Vincent
- Published
- 2015
- Full Text
- View/download PDF
7. IOA-04 - Dermo-hypodermite chronique associée à une ostéoradionécrose de la paroi thoracique après un cancer du sein : problèmes thérapeutiques à propos de 4 cas
- Author
-
Cordier, J., Leroy, E., Boldron, A., Beuze, F., Verhaeghe, A., Dehecq, C., Chossière, L., and Senneville, E.
- Published
- 2016
- Full Text
- View/download PDF
8. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Author
-
Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, C, Pagnoux, C, Jayne, D, Guillevin, L, Cordier, J, Sinico, Ra, Cordier, J., Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, C, Pagnoux, C, Jayne, D, Guillevin, L, Cordier, J, Sinico, Ra, and Cordier, J.
- Abstract
Objective: To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods: Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. Results: The study population included 157 patients (mean age 49.4. ±. 14.1), with a follow-up of 7.4. ±. 6.4. years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p. =0.005) and with the presence of ANCA (p. <. 0.001). Overall, 59% of patients had . polyangiitis as defined by definite vasculitis, strong surrogate of vasculitis, mononeuritis multiplex, and/or ANCA with at least one systemic manifestation other than ENT or respiratory. Patients with . polyangiitis had more systemic manifestations including arthralgias (p. =0.02) and renal disease (p. =0.024), had higher peripheral eosinophilia (p. =0.027), and a trend towards less myocarditis (p. =0.057). Using predefined criteria of vasculitis and surrogates of vasculitis, ANCA alone were found to be insufficient to categorise patients with vasculitis features. Conclusion: We suggest a revised nomenclature and definition for EGPA and a new proposed entity referred to as hypereosinophilic asthma with systemic (non vasculitic) manifestations
- Published
- 2017
9. Le risque économique : la difficile agrégation des risques à l’échelle des exploitations et des filières. Innovations Agronomiques 77, 1-11
- Author
-
Phélippé-Guinvarc’h, M. and Cordier, J.
- Published
- 2019
- Full Text
- View/download PDF
10. Le risque économique : la difficile agrégation des risques à l'échelle des exploitations et des filières
- Author
-
Phélippé-Guinvarc'h, Martial, Cordier, J., Groupe d'Analyse des Itinéraires et des Niveaux Salariaux (GAINS), and Le Mans Université (UM)
- Subjects
[SDV.SA]Life Sciences [q-bio]/Agricultural sciences ,Risk Management ,[SHS.STAT]Humanities and Social Sciences/Methods and statistics ,[QFIN]Quantitative Finance [q-fin] ,[SDV.SA.AEP]Life Sciences [q-bio]/Agricultural sciences/Agriculture, economy and politics ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,Gestion des risques ,[STAT]Statistics [stat] ,Mots-clés : Cumul de risques ,Accumulated risk ,Extreme Value Theory ,Copulas ,Théorie des valeurs extrêmes ,Copules - Abstract
International audience; Economic risk: The challenging aggregation of risks across the farms and sectors The article explains the relevance of the copula and the theory of extreme values in the evaluation of agricultural risk. In the classical approach, the multiple risks allow a diversification of the risks, bringing useful financial compensations within the exploitation or the sector. This approach is widely used in portfolio management according to the central limit theorem (CLT). The article outlines and illustrates the cases where the CLT is not applicable because of the form of the statistical links, the loss evaluation or the extreme values.; L'article expose l'intérêt de la théorie des copules et des valeurs extrêmes dans l'évaluation du risque agricole. Dans une approche classique, les multiples risques sont agrégés selon une diversification des risques, apportant des compensations économiques utiles au sein de l'exploitation ou de la filière. Elle est largement utilisée en gestion de portefeuille et s'appuie sur le théorème central limite (TCL). L'article expose et illustre les cas où le TCL ne s'applique pas à cause de la forme des liens statistiques, de l'évaluation de l'impact économique ou des valeurs extrêmes.
- Published
- 2019
11. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Author
-
Cottin , V., Bel , E., Bottero , P., Dalhoff , K., Humbert , M., Lazor , R., Sinico , R.A., Sivasothy , P., Wechsler , M.E., Groh , M., Marchand-Adam , S., Khouatra , C., Wallaert , B., Taillé , C., Delaval , P., Cadranel , J., Bonniaud , P., Prévot , G., Hirschi , S., Gondouin , A., Dunogué , B., Chatté , G., Briault , C., Pagnoux , C., Jayne , D., Guillevin , L., Cordier , J.-F., Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of Pneumology [Lyon], Hospices Civils de Lyon (HCL), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Universität zu Lübeck = University of Lübeck [Lübeck], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université de Lausanne = University of Lausanne (UNIL), Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, University of Colorado Anschutz [Aurora], Pathologies Respiratoires : Protéolyse et Aérosolthérapie, Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Pneumologie [Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Centre de Compétence pour les Maladies Pulmonaires Rares, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Theranoscan, Université Pierre et Marie Curie - Paris 6 (UPMC), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service des maladies respiratoires [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Protéines de choc thermique : mort cellulaire, différenciation cellulaire et propriétés tumorigéniques (U866, Cancer, équipe 3), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, European Respiratory Society ERS TF 2008-08, Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, C, Pagnoux, C, Jayne, D, Guillevin, L, Cordier, J, Universität zu Lübeck [Lübeck], Université de Lausanne (UNIL), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hospices Civils de Lyon ( HCL ), Academic Medical Center [Amsterdam] ( AMC ), University of Amsterdam [Amsterdam] ( UvA ), Université de Lausanne ( UNIL ), University of Colorado Health Sciences Center and National Jewish Medical and Research Center, Université de Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Pneumologie et Immuno-Allergologie, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre de Compétence pour les Maladies Pulmonaires Rares, Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Service de pneumologie et réanimation [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Université Pierre et Marie Curie - Paris 6 ( UPMC ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Université Claude Bernard Lyon 1 ( UCBL ), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA)
- Subjects
Adult ,Male ,[SDV.EE]Life Sciences [q-bio]/Ecology, environment ,Vasculiti ,ANCA ,Eosinophilic granulomatosis with polyangiitis ,Immunology ,Churg-Strauss syndrome ,Middle Aged ,Prognosis ,Asthma ,vasculitis ,[ SDV.EE ] Life Sciences [q-bio]/Ecology, environment ,Treatment Outcome ,classification ,diagnostic criteria ,Eosinophilic granulomatosis with polyangiiti ,Humans ,Immunology and Allergy ,Female ,Immunosuppressive Agents ,Retrospective Studies - Abstract
International audience; Objective To guide nosology and classification of patients with eosinophilic granulomatosis with polyangiitis (EGPA) based on phenotype and presence or absence of ANCA. Methods Organ manifestations and ANCA status were retrospectively analyzed based on the presence or not of predefined definite vasculitis features or surrogates of vasculitis in patients asthma, eosinophilia, and at least one systemic organ manifestation attributable to systemic disease. Results The study population included 157 patients (mean age 49.4 ± 14.1), with a follow-up of 7.4 ± 6.4 years. Patients with ANCA (31%) more frequently had weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of arterial wall on biopsy, and other renal disease. A total of 41% of patients had definite vasculitis manifestations (37%) or strong surrogates of vasculitis (4%), of whom only 53% had ANCA. Mononeuritis multiplex was associated with systemic vasculitis (p = 0.005) and with the presence of ANCA (p
- Published
- 2017
12. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Author
-
Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., SINICO, RENATO ALBERTO, Cottin, V, Bel, E, Bottero, P, Dalhoff, K, Humbert, M, Lazor, R, Sinico, R, Sivasothy, P, Wechsler, M, Groh, M, Marchand Adam, S, Khouatra, C, Wallaert, B, Taillé, C, Delaval, P, Cadranel, J, Bonniaud, P, Prévot, G, Hirschi, S, Gondouin, A, Dunogué, B, Chatté, G, Briault, A, Jayne, D, Guillevin, L, Cordier, J, Cordier, J., and SINICO, RENATO ALBERTO
- Abstract
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail. In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease. The study population included 157 patients (mean±SD age 49.4±14.1 years), with a mean±SD blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±SD of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively. In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity.
- Published
- 2016
13. A 12-WEEK COMBINATION OF CLARITHROMYCIN AND PREDNISONE COMPARED TO A 24-WEEK PREDNISONE ALONE TREATMENT IN CRYPTOGENIC AND RADIATION-INDUCED ORGANIZING PNEUMONIA
- Author
-
Petitpierre, N., Cottin, V., sylvain marchand-adam, Hirschi, S., Rigaud, D., Court-Fortune, I., Jouneau, S., Israël-Biet, D., Molard, A., Cordier, J. -F, Lazor, R., Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Service de Pneumologie [Hôpital Louis Pradel – CHU Lyon] (Centre de Référence des Maladies Pulmonaires Rares), CHU Lyon-Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Strasbourg, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), CHU Pontchaillou [Rennes], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-CHU Lyon, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
Original Article: Clinical Research ,recurrence ,glucocorticoids ,cryptogenic organizing pneumonia ,[SDV]Life Sciences [q-bio] ,treatment outcome ,interstitial ,clarithromycin ,lung diseases - Abstract
Background: Some data suggest that anti-inflammatory macrolides may be effective to treat organizing pneumonia (OP) and prevent relapses, but no formal comparison with prednisone alone is available. To explore this issue, we retrospectively compared the efficacy of a 12-week combined regimen of clarithromycin and prednisone with a 24-week prednisone alone regimen in OP. Methods: A standard 12-week regimen of combined clarithromycin and prednisone was designed for the treatment of cryptogenic or radiation-induced OP, aiming at reducing the cumulated prednisone dose and the relapse rate. Its use was left to the discretion of the treating physicians, members of the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Data were compared to a historical control group treated with a standard 24-week prednisone alone regimen. Results: 16 patients were treated with combined therapy and 21 with prednisone alone. Complete radiological remission was achieved in 63% of the combined therapy group and 81% of the prednisone alone group (p=0.38). Symptomatic relapses occurred in 81% of the combined therapy group, and 52% of the prednisone alone group (p=0.14). No side effect of clarithromycin was reported. Conclusions: In patients with cryptogenic or radiation-induced OP, a 12-week regimen of clarithromycin and prednisone showed no benefit on remission rate and relapse rate as compared to a 24-week prednisone only regimen. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 230-238)
- Published
- 2018
14. S.4.1 N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc
- Author
-
Thakkar, V., Stevens, W., Prior, D., Byron, J., Patterson, K., Hissaria, P., Moore, O., Roddy, J., Zochling, J., Sahhar, J., Nash, P., Tymms, K., Youssef, P., Proudman, S., Nikpour, M., Launay, D., Sitbon, O., Cordier, J. F., Hachulla, E., Mouthon, L., Gressin, V., Rottat, L., Clerson, P., Simonneau, G., Humbert, M., Carreira, P., Carmona, L., Joven, B. E., Denton, C. P., Allanore, Y., Walker, U. A., Matucci-Cerinic, M., Muller-Ladner, U., Hsu, V., Cheng, Q., and Steen, V.
- Abstract
Introduction. Pulmonary arterial hypertension (PAH) is a major cause of mortality in SSc. NT-proBNP may be a useful biomarker of prevalent PAH but its role in screening for incident PAH has not been evaluated. Methods. Patients recruited into the Australian Scleroderma Cohort Study undergo annual echocardiography, pulmonary function tests (PFTs), 6-min walk test (6MWT) and have serum NT-proBNP measured (ElecsysproBNP II). The diagnosis of PAH is based on Dana point criteria at right heart catheterization (RHC). Patients with LV dysfunction or eGFR 36 mmHg, (ii) FVC/DLCO% >1.6 and no significant ILD, (iii) DLCO 189.2 pg/ml had a likelihood ratio of 26.4 for presence of PAH (c-statistic = 0.9; sensitivity 85%; specificity 97%). An NT-proBNP level 189.2 pg/ml and
- Published
- 2017
15. RETRAIT : Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique : actualisation 2017. Résumé
- Author
-
Cottin, V., Crestani, B., Cadranel, J., Cordier, J.-F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J.-C., Dromer, C., Gomez, E., Israel-Biet, D., Jouneau, S., Kessler, R., Marquette, C.-H., Reynaud-Gaubert, M., Aguilaniu, B., Bonnet, D., Carré, P., Danel, C., Faivre, J.-B., Ferretti, G., Just, N., Lebargy, F., Philippe, B., Terrioux, P., Thivolet-Béjui, F., Trumbic, B., and Valeyre, D.
- Abstract
L’éditeur a le regret de vous informer que cet article ayant déjà été publié dans Rev Mal Respir2017;34:834–851. Doi : 10.1016/j.rmr.2017.07.022. Cette seconde publication faite par erreur a été retirée.
- Published
- 2024
- Full Text
- View/download PDF
16. RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2017. Version courte
- Author
-
Cottin, V., Crestani, B., Cadranel, J., Cordier, J.-F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J.-C., Dromer, C., Gomez, E., Israel-Biet, D., Jouneau, S., Kessler, R., Marquette, C.-H., Reynaud-Gaubert, M., Aguilaniu, B., Bonnet, D., Carré, P., Danel, C., Faivre, J.-B., Ferretti, G., Just, N., Lebargy, F., Philippe, B., Terrioux, P., Thivolet-Béjui, F., Trumbic, B., and Valeyre, D.
- Abstract
L’éditeur a le regret de vous informer que cet article ayant déjà été publié dans Rev Mal Respir2017;34:852–899. Doi: 10.1016/j.rmr.2017.07.019. Cette seconde publication faite par erreur a été retirée.
- Published
- 2024
- Full Text
- View/download PDF
17. RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique–Actualisation 2017. Version longue
- Author
-
Cottin, V., Crestani, B., Cadranel, J., Cordier, J.-F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J.-C., Dromer, C., Gomez, E., Israel-Biet, D., Jouneau, S., Kessler, R., Marquette, C.-H., Reynaud-Gaubert, M., Aguilaniu, B., Bonnet, D., Carré, P., Danel, C., Faivre, J.-B., Ferretti, G., Just, N., Lebargy, F., Philippe, B., Terrioux, P., Thivolet-Béjui, F., Trumbic, B., and Valeyre, D.
- Abstract
L’éditeur a le regret de vous informer que cet article ayant déjà été publié dans Rev Mal Respir2017;34:900–68. Doi: 10.1016/j.rmr.2017.07.017. Cette seconde publication faite par erreur a été retirée.
- Published
- 2024
- Full Text
- View/download PDF
18. Lymphome de type Mucosa-Associated Lymphoid Tissue, (MALT) pulmonaire, puis gastrique
- Author
-
Merveilleux du Vignaux, C., Girard, N., Salles, G., and Cordier, J.-F.
- Published
- 2016
- Full Text
- View/download PDF
19. MSR135 Do You Really Need to See the Doctor? Developing a Machine Learning Approach for Optimal Assignment Rules of Physician Visits for Patients After Knee Replacement.
- Author
-
Cordier, J., Langenberger, B., Salvi, I., Kuklinski, D., and Geissler, A.
- Subjects
- *
TOTAL knee replacement , *PHYSICIAN services utilization , *MACHINE learning , *KNEE , *PHYSICIANS - Published
- 2023
- Full Text
- View/download PDF
20. RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2017. Version courte
- Author
-
Cottin, V., primary, Crestani, B., additional, Cadranel, J., additional, Cordier, J.-F., additional, Marchand-Adam, S., additional, Prévot, G., additional, Wallaert, B., additional, Bergot, E., additional, Camus, P., additional, Dalphin, J.-C., additional, Dromer, C., additional, Gomez, E., additional, Israel-Biet, D., additional, Jouneau, S., additional, Kessler, R., additional, Marquette, C.-H., additional, Reynaud-Gaubert, M., additional, Aguilaniu, B., additional, Bonnet, D., additional, Carré, P., additional, Danel, C., additional, Faivre, J.-B., additional, Ferretti, G., additional, Just, N., additional, Lebargy, F., additional, Philippe, B., additional, Terrioux, P., additional, Thivolet-Béjui, F., additional, Trumbic, B., additional, and Valeyre, D., additional
- Published
- 2017
- Full Text
- View/download PDF
21. RETRAIT : Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique : actualisation 2017. Résumé
- Author
-
Cottin, V., primary, Crestani, B., additional, Cadranel, J., additional, Cordier, J.-F., additional, Marchand-Adam, S., additional, Prévot, G., additional, Wallaert, B., additional, Bergot, E., additional, Camus, P., additional, Dalphin, J.-C., additional, Dromer, C., additional, Gomez, E., additional, Israel-Biet, D., additional, Jouneau, S., additional, Kessler, R., additional, Marquette, C.-H., additional, Reynaud-Gaubert, M., additional, Aguilaniu, B., additional, Bonnet, D., additional, Carré, P., additional, Danel, C., additional, Faivre, J.-B., additional, Ferretti, G., additional, Just, N., additional, Lebargy, F., additional, Philippe, B., additional, Terrioux, P., additional, Thivolet-Béjui, F., additional, Trumbic, B., additional, and Valeyre, D., additional
- Published
- 2017
- Full Text
- View/download PDF
22. RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique–Actualisation 2017. Version longue
- Author
-
Cottin, V., primary, Crestani, B., additional, Cadranel, J., additional, Cordier, J.-F., additional, Marchand-Adam, S., additional, Prévot, G., additional, Wallaert, B., additional, Bergot, E., additional, Camus, P., additional, Dalphin, J.-C., additional, Dromer, C., additional, Gomez, E., additional, Israel-Biet, D., additional, Jouneau, S., additional, Kessler, R., additional, Marquette, C.-H., additional, Reynaud-Gaubert, M., additional, Aguilaniu, B., additional, Bonnet, D., additional, Carré, P., additional, Danel, C., additional, Faivre, J.-B., additional, Ferretti, G., additional, Just, N., additional, Lebargy, F., additional, Philippe, B., additional, Terrioux, P., additional, Thivolet-Béjui, F., additional, Trumbic, B., additional, and Valeyre, D., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Environmental monitoring and modelling
- Author
-
Labat, N, Lescanne, Marc, Hy-Billiot, Joelle, De Donato, Philippe, Cosson, Michel, Luzzalo, T, Legay, Philippe, Mora, F, Pichon, C, Cordier, J, Dellong, M, Mathieu, F, UL, Georessources, GeoRessources, and Institut national des sciences de l'Univers (INSU - CNRS)-Centre de recherches sur la géologie des matières premières minérales et énergétiques (CREGU)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDU] Sciences of the Universe [physics] ,[SDU]Sciences of the Universe [physics] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2015
24. Intérêt d’un test d’exercice à charge constante chez les patients présentant une fibrose pulmonaire idiopathique
- Author
-
Imamdad, P., primary, Turquier, S., additional, Surpas, P., additional, Cottin, V., additional, Cordier, J., additional, and Glerant, J., additional
- Published
- 2016
- Full Text
- View/download PDF
25. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
- Author
-
Groh, M, Pagnoux, C, Baldini, C, Bel, E, Bottero, P, Cottin, V, Dalhoff, K, Dunogué, B, Gross, W, Holle, J, Humbert, M, Jayne, D, Jennette, J, Lazor, R, Mahr, A, Merkel, P, Mouthon, L, Sinico, R, Specks, U, Vaglio, A, Wechsler, M, Cordier, J, Guillevin, L, Guillevin, L., SINICO, RENATO ALBERTO, Groh, M, Pagnoux, C, Baldini, C, Bel, E, Bottero, P, Cottin, V, Dalhoff, K, Dunogué, B, Gross, W, Holle, J, Humbert, M, Jayne, D, Jennette, J, Lazor, R, Mahr, A, Merkel, P, Mouthon, L, Sinico, R, Specks, U, Vaglio, A, Wechsler, M, Cordier, J, Guillevin, L, Guillevin, L., and SINICO, RENATO ALBERTO
- Abstract
Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
- Published
- 2015
26. Projecting Different Identities: A Longitudinal Study of the “Whipsaw” Effects of Changing Leadership Discourse About the Triple Bottom Line
- Author
-
Moingeon, Bertrand, Mirvis, P., Bayle-Cordier, J., Moingeon, Bertrand, Mirvis, P., and Bayle-Cordier, J.
- Abstract
This paper focuses on changes in leadership’s discourse about the “triple bottom line” in Ben & Jerry’s ice cream from its founding days through to its acquisition by and integration into Unilever. For this study, we analyzed CEO claims about “who we are” from their letters in annual reports (what we label projected identity). A sample of employees (both long-service and relative newcomers) were interviewed about their perceptions of B&J’s over the thirty years covered. Findings reveal that successive CEO’s stressed different “logics” about the business and what would make it successful over the years with the founders emphasizing a strong linkage between the economic, product, and social components of the company’s triple bottom line and their next three successors decoupling these components and pushing, each in different ways, for stronger financial returns. As a result, organization members were “whipsawed” between their CEOs’ different logics and identity claims. The CEO letters exhibit a progression over time from a more normative to utilitarian tone familiar in the organizational identity literature. The messaging shifts, however, when a fifth CEO takes charge and re-integrates the firm’s triple bottom line. Thus the firm’s projected identity evolved in a U pattern starting with an integrated triple bottom line logic, shifting to a more linear logic where the economic mission dominates, and then reintegration where multiple bottom lines are embraced once again. Here we explore both the strategic (external) and personal (internal) challenges informing the different CEOs’ messages over years, the whipsaw effect on staff, and the longer term evolution of projected identity in the company and reemergence of its integrated triple bottom line. This study contributes to the CSR and organization identity literatures by documenting how CEO’s (and their company) must struggle with maintaining an integrated triple bottom line in the context of commercial challenges and
- Published
- 2015
27. Perioperatives Outcome in Korrelation zur Lernkurve bei robotisch assistierter partieller Nephrektomie: Die ersten 109 Fälle unserer Klinik
- Author
-
Cordier, J., additional, Neisius, A., additional, Thomas, C., additional, Hampel, C., additional, Thüroff, J., additional, Brenner, W., additional, and Roos, F., additional
- Published
- 2015
- Full Text
- View/download PDF
28. Cognitive and motor aspects of a coincidence-timing task in Cerebral Palsy children
- Author
-
Olivier, I., primary, Baker, C., additional, Cordier, J., additional, Thomann, G., additional, and Nougier, V., additional
- Published
- 2015
- Full Text
- View/download PDF
29. 3e Journée française de la fibrose pulmonaire idiopathique. 19 septembre 2014
- Author
-
Cottin, V., primary, Crestani, B., additional, Danel, C., additional, Debray, M.-P., additional, Nunes, H., additional, Poletti, V., additional, Prévost, G., additional, Vergnon, J.-M., additional, Wallaert, B., additional, and Cordier, J.-F., additional
- Published
- 2015
- Full Text
- View/download PDF
30. Seconde enquête de pratique sur la prise en charge de la fibrose pulmonaire idiopathique en France
- Author
-
Cottin, V., primary, Bergot, E., additional, Bourdin, A., additional, Cadranel, J., additional, Camus, P., additional, Crestani, B., additional, Dalphin, J.-C., additional, Dromer, C., additional, Israel-Biet, D., additional, Jouneau, S., additional, Kessler, R., additional, Marchand-Adam, G., additional, Marquette, C.H., additional, Prévot, G., additional, Reynaud-Gaubert, M., additional, Valeyre, D., additional, Wallaert, B., additional, Bouquillon, B., additional, and Cordier, J.-F., additional
- Published
- 2015
- Full Text
- View/download PDF
31. Comorbidités au cours du syndrome emphysème-fibrose
- Author
-
Ahmad, K.-A.-K., primary, Gamondes, D.-G.-D., additional, Souverain, E.-S.-E., additional, Cordier, J.-F.-C.-J.-F., additional, and Cottin, V.-C.-V., additional
- Published
- 2015
- Full Text
- View/download PDF
32. Maladies pulmonaires rares : de l’adoption des maladies orphelines à la structuration de la filière de soins
- Author
-
Cottin, V., primary and Cordier, J.-F., additional
- Published
- 2014
- Full Text
- View/download PDF
33. Pneumopathie infiltrante diffuse associée à une dermatomyosite amyopathique avec auto-anticorps anti-MDA5
- Author
-
Gerfaud-Valentin, M., primary, Ahmad, K., additional, Piegay, F., additional, Fabien, N., additional, Raphanel, B., additional, Cordier, J.-F., additional, and Cottin, V., additional
- Published
- 2014
- Full Text
- View/download PDF
34. 3eJournée française de la fibrose pulmonaire idiopathique. 19 septembre 2014
- Author
-
Cottin, V., Crestani, B., Danel, C., Debray, M.-P., Nunes, H., Poletti, V., Prévost, G., Vergnon, J.-M., Wallaert, B., and Cordier, J.-F.
- Published
- 2015
- Full Text
- View/download PDF
35. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management
- Author
-
David Jayne, Romain Lazor, Jean-François Cordier, Ulrich Specks, Marc Humbert, Klaus Dalhoff, Wolfgang L. Gross, Vincent Cottin, Peter A. Merkel, Matthieu Groh, Augusto Vaglio, Alfred Mahr, Paolo Bottero, Renato Alberto Sinico, Bertrand Dunogué, J. Charles Jennette, Loïc Guillevin, Christian Pagnoux, Michael E. Wechsler, Julia U Holle, Luc Mouthon, Chiara Baldini, Elisabeth H. Bel, Groh, M, Pagnoux, C, Baldini, C, Bel, E, Bottero, P, Cottin, V, Dalhoff, K, Dunogué, B, Gross, W, Holle, J, Humbert, M, Jayne, D, Jennette, J, Lazor, R, Mahr, A, Merkel, P, Mouthon, L, Sinico, R, Specks, U, Vaglio, A, Wechsler, M, Cordier, J, Guillevin, L, AII - Amsterdam institute for Infection and Immunity, and Pulmonology
- Subjects
United State ,medicine.medical_specialty ,Consensus ,Advisory Committees ,Churg-Strauss syndrome ,MEDLINE ,Consensu ,Recommendations ,Immunosuppressive Agent ,Glucocorticoid ,Eosinophilic ,Eosinophilia ,Internal Medicine ,Medicine ,Humans ,Churg–Strauss syndrome ,Disease management (health) ,Glucocorticoids ,Churg strauss ,Pulmonologists ,Advisory Committee ,business.industry ,Task force ,Eosinophilic granulomatosis with polyangiitis ,Medicine (all) ,Granulomatosis with Polyangiitis ,Disease Management ,Evidence-based medicine ,Recommendation ,medicine.disease ,United States ,Asthma ,Surgery ,Europe ,Anti-neutrophil cytoplasm antibody-associated vasculitis ,Anti-neutrophil cytoplasm antibody-associated vasculiti ,Family medicine ,Eosinophilic granulomatosis with polyangiiti ,Granulomatosis with Polyangiiti ,business ,Granulomatosis with polyangiitis ,Rituximab ,Churg-Strauss Syndrome ,Immunosuppressive Agents ,Human - Abstract
Objective To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) (EGPA). Methods The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Results Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. Discussion These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.
- Published
- 2015
36. Orphan lung diseases from definition to organisation of care
- Author
-
Jean-François Cordier, Vincent Cottin, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École pratique des hautes études (EPHE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Cottin, V. and Cordier, J. F. and Richeldi, L., Chautard, Marie-Gabrielle, Cottin, V. and Cordier, J. F. and Richeldi, L., Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL)
- Subjects
medicine.medical_specialty ,Pediatrics ,Lung ,business.industry ,[SDV]Life Sciences [q-bio] ,Disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Clinical research ,030228 respiratory system ,Drug development ,Epidemiology ,medicine ,030212 general & internal medicine ,Intensive care medicine ,business ,ComputingMilieux_MISCELLANEOUS - Abstract
The rare diseases have been called “orphan” because this term means that patients affected by such conditions feel that most physicians are reluctant to care for their disease because of its rarity, and that insufficient research is developed to improve diagnosis, clinical management, and especially the more distressing manifestations. The patients with rare diseases thus feel abandoned and orphan when comparing with patients with common diseases who benefit from extensive research worldwide and continuous drug development.
- Published
- 2015
37. Ifanosine: Olea europaea L. and Hyphaene thebaica L. combination, from traditional utilization to rational formulation: Preclinical and clinical efficacy on hypertensives patients.
- Author
-
Zakraoui M, Outman A, Kinambamba MS, Bouhrim M, Ndjib RC, Al Kamaly O, Alshawwa SZ, Seid AB, Cordier J, Ngoupayo J, Longo-Mbenza B, Gressier B, Parvez MK, Pasković I, Hamrouni L, and Eto B
- Subjects
- Humans, Rats, Animals, Antihypertensive Agents pharmacology, Antihypertensive Agents therapeutic use, Antihypertensive Agents analysis, Plant Extracts pharmacology, Plant Extracts therapeutic use, Plant Extracts chemistry, Plant Leaves chemistry, Treatment Outcome, Olea chemistry, Hypertension drug therapy
- Abstract
Ethnopharmacological Relevance: Olea europaea L. and Hyphaene thebaica L. are commonly employed by traditional healers in Africa for treating and preventing hypertension, either individually or in a polyherbal preparation (Ifanosine)., Aim of the Study: The primary aim was to assess the antihypertensive effects of Olea europaea L. leaves aqueous extract (OEL), Hyphaene thebaica L. mesocarp extract (HT), and the Ifanosine on isolated rat aorta rings. The secondary objective was to evaluate the clinical benefits of a new oral formulation of Ifanosine., Materials and Methods: In vitro studies using an isometric transducer examined the antihypertensive effects of HT, OEL, and Ifanosine on rat aorta. Ussing chambers technic were employed to measure mucosal to serosal fluxes and total transepithelial electrical conductance (Gt) to assess the intestinal bioavailability of HT, OEL, and Ifanosine. HPLC was utilized to determine the phytochemical composition of OEL and HT extracts. Subchronic toxicity investigations involved two groups of rats, treated with either water (control) or Ifanosine at 5 g/kg for 28 days. Clinical benefits of the new Ifanosine formulation were evaluated in an observational study with 32 hypertensive patients receiving a fixed oral dose of 3.5 mg three times a day for 30 days., Results: Aqueous extracts induced dose-dependent relaxation of rat aorta rings, with HT and OEL having higher IC50 values than Ifanosine (IC50 = 44.76 ± 1.35 ng/mL, 58.67 ± 1.02 ng/mL, and 29.46 ± 0.26 ng/mL, respectively). The pA2 values of OEL and HT were 1 and 0.6, respectively, while Ifanosine was 0.06. Intestinal bioavailability studies revealed better Prazosin bioavailability than plant extracts. Toxicological studies demonstrated the safety of Ifanosine, supported by histological examinations and biochemical parameters in rat blood. Biochemical analyses indicated flavonoids and phenolic acids as dominant active constituents. Clinical benefits in humans included reduced SBP, DBP, LDL-c, VLDL-c, and TAG, and increased HDL-c without overt adverse effects., Conclusion: This study validates the traditional use of OEL and HT for hypertension and advocates for alternative and combinatorial polyphytotherapy (ACP) to enhance traditional remedies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Medication adherence halves COPD patients' hospitalization risk - evidence from Swiss health insurance data.
- Author
-
Bischof AY, Cordier J, Vogel J, and Geissler A
- Subjects
- Humans, Switzerland, Retrospective Studies, Hospitalization, Medication Adherence, Insurance, Health, Disease Progression, Pulmonary Disease, Chronic Obstructive
- Abstract
Medication adherence is vital for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) to mitigate long-term consequences. The impact of poor medication adherence on inferior outcomes like exacerbations leading to hospital admissions is yet to be studied using real-world data. Using Swiss claims data from 2015-2020, we group patients into five categories according to their medication possession ratio. By employing a logistic regression, we quantify each category's average treatment effect of the medication possession ratio on hospitalized exacerbations. 13,557 COPD patients are included in the analysis. Patients with high medication adherence (daily medication reserve of 80% to 100%) are 51% less likely to incur exacerbation following a hospital stay than patients with the lowest medication adherence (daily medication reserve of 0% to 20%). The study shows that medication adherence varies strongly among Swiss COPD patients. Furthermore, high medication adherence immensely decreases the risk of hospitalized exacerbations., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
39. Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression.
- Author
-
Zhigulev A, Norberg Z, Cordier J, Spalinskas R, Bassereh H, Björn N, Pradhananga S, Gréen H, and Sahlén P
- Subjects
- Humans, Carboplatin adverse effects, Mutation genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Antineoplastic Agents adverse effects
- Abstract
Non-small cell lung cancer is often diagnosed at advanced stages, and many patients are still treated with classical chemotherapy. The unselective nature of chemotherapy often results in severe myelosuppression. Previous studies showed that protein-coding mutations could not fully explain the predisposition to myelosuppression. Here, we investigate the possible role of enhancer mutations in myelosuppression susceptibility. We produced transcriptome and promoter-interaction maps (using HiCap) of three blood stem-like cell lines treated with carboplatin or gemcitabine. Taking advantage of publicly available enhancer datasets, we validated HiCap results in silico and in living cells using epigenetic CRISPR technology. We also developed a network approach for interactome analysis and detection of differentially interacting genes. Differential interaction analysis provided additional information on relevant genes and pathways for myelosuppression compared with differential gene expression analysis at the bulk level. Moreover, we showed that enhancers of differentially interacting genes are highly enriched for variants associated with differing levels of myelosuppression. Altogether, our work represents a prominent example of integrative transcriptome and gene regulatory datasets analysis for the functional annotation of noncoding mutations., (© 2024 Zhigulev et al.)
- Published
- 2024
- Full Text
- View/download PDF
40. Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients.
- Author
-
Daccord C, Cottin V, Prévot G, Uzunhan Y, Mornex JF, Bonniaud P, Borie R, Briault A, Collonge-Rame MA, Crestani B, Devouassoux G, Freynet O, Gondouin A, Hauss PA, Khouatra C, Leroy S, Marchand-Adam S, Marquette C, Montani D, Naccache JM, Nadeau G, Poulalhon N, Reynaud-Gaubert M, Salaun M, Wallaert B, Cordier JF, Faouzi M, and Lazor R
- Subjects
- Child, Humans, Lung, Retrospective Studies, Birt-Hogg-Dube Syndrome genetics, Lung Diseases genetics, Pneumothorax genetics
- Abstract
Background: Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder caused by mutations in the FLCN gene coding for folliculin. Its clinical expression includes cutaneous fibrofolliculomas, renal tumors, multiple pulmonary cysts, and recurrent spontaneous pneumothoraces. Data on lung function in BHD are scarce and it is not known whether lung function declines over time. We retrospectively assessed lung function at baseline and during follow-up in 96 patients with BHD., Results: Ninety-five percent of BHD patients had multiple pulmonary cysts on computed tomography and 59% had experienced at least one pneumothorax. Mean values of forced expiratory volume in 1 second (FEV
1 ), forced vital capacity (FVC), FEV1 /FVC ratio, and total lung capacity were normal at baseline. Mean (standard deviation) residual volume (RV) was moderately increased to 116 (36) %pred at baseline, and RV was elevated > 120%pred in 41% of cases. Mean (standard deviation) carbon monoxide transfer factor (DLco) was moderately decreased to 85 (18) %pred at baseline, and DLco was decreased < 80%pred in 33% of cases. When adjusted for age, gender, smoking and history of pleurodesis, lung function parameters did not significantly decline over a follow-up period of 6 years., Conclusions: Cystic lung disease in BHD does not affect respiratory function at baseline except for slightly increased RV and reduced DLco. No significant deterioration of lung function occurs in BHD over a follow-up period of 6 years.- Published
- 2020
- Full Text
- View/download PDF
41. Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality.
- Author
-
Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeyre D, Nunes H, Hachulla E, Launay D, Crestani B, Cazalets C, Jego P, Bussone G, Bérezné A, Guillevin L, Revel MP, Cordier JF, and Mouthon L
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Female, Humans, Lung diagnostic imaging, Male, Middle Aged, Prognosis, Pulmonary Emphysema diagnostic imaging, Pulmonary Emphysema physiopathology, Pulmonary Fibrosis diagnostic imaging, Pulmonary Fibrosis physiopathology, Radiography, Thoracic, Respiratory Function Tests, Retrospective Studies, Scleroderma, Systemic diagnostic imaging, Scleroderma, Systemic physiopathology, Tomography, X-Ray Computed, Young Adult, Lung physiopathology, Pulmonary Emphysema complications, Pulmonary Fibrosis complications, Scleroderma, Systemic complications
- Abstract
Background: The syndrome of combined pulmonary fibrosis and emphysema (CPFE) primarily due to tobacco smoking has been reported in connective tissue disease, but little is known about its characteristics in systemic sclerosis (SSc)., Methods: In this retrospective multi-center case-control study, we identified 36 SSc patients with CPFE, and compared them with 72 SSc controls with interstitial lung disease (ILD) without emphysema., Results: Rate of CPFE in SSc patients with CT scan was 3.6%, and 7.6% among SSc patients with ILD. CPFE-SSc patients were more likely to be male (75 % vs 18%, p < 0.0001), smokers (83 % vs 33%, p < 0.0001), and to have limited cutaneous SSc (53 % vs 24% p < 0.01) than ILD-SSc controls. No specific autoantibody was significantly associated with CPFE. At diagnosis, CPFE-SSc patients had a greater decrease in carbon monoxide diffusing capacity (DLCO 39 ± 13 % vs 51 ± 12% of predicted value, p < 0.0001) when compared to SSc-ILD controls, whereas lung volumes (total lung capacity and forced vital capacity) were similar. During follow-up, CPFE-SSc patients more frequently developed precapillary pulmonary hypertension (PH) (44 % vs 11%, p < 10
-4 ), experienced more frequent unscheduled hospitalizations (50 % vs 25%, p < 0.01), and had decreased survival (p < 0.02 by Kaplan-Meier survival analysis) as compared to ILD-SSc controls., Conclusions: The CPFE syndrome is a distinct pulmonary manifestation in SSc, with higher morbidity and mortality. Early diagnosis of CPFE by chest CT in SSc patients (especially smokers) may result in earlier smoking cessation, screening for PH, and appropriate management., (Copyright © 2018. Published by Elsevier Inc.)- Published
- 2019
- Full Text
- View/download PDF
42. Diffuse bronchiectasis and airflow obstruction in granulomatosis with polyangiitis.
- Author
-
Barba T, Khouatra C, Traclet J J, Cordier JF, and Cottin V
- Abstract
Parenchymal lung nodes and diffuse intra-alveolar hemorrhage are the archetypal pulmonary manifestations of Granulomatosis with Polyangiitis (GPA). The occurrence of diffuse bronchiectasis and airflow obstruction during GPA is unusual. We report here 3 patients with GPA who developed diffuse bronchiectasis during follow-up. The airflow obstruction seemed then to evolve independently from the GPA itself and ultimately led to respiratory insufficiency. Bronchiectases promoted the occurrence of opportunistic infections, especially with atypical mycobacteria. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 81-84) ., (Copyright: © 2018.)
- Published
- 2018
- Full Text
- View/download PDF
43. [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update].
- Author
-
Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prévot G, Wallaert B, Bergot E, Camus P, Dalphin JC, Dromer C, Gomez E, Israel-Biet D, Jouneau S, Kessler R, Marquette CH, Reynaud-Gaubert M, Aguilaniu B, Bonnet D, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Lebargy F, Philippe B, Terrioux P, Thivolet-Béjui F, Trumbic B, and Valeyre D
- Published
- 2017
- Full Text
- View/download PDF
44. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
- Author
-
Chebib N, Khouatra C, Lazor R, Archer F, Leroux C, Gamondes D, Thivolet-Bejui F, Cordier JF, and Cottin V
- Subjects
- Adult, Female, History, 20th Century, History, 21st Century, Humans, Lung Neoplasms diagnosis, Lung Neoplasms epidemiology, Lung Neoplasms etiology, Lung Neoplasms therapy, Lymphangioleiomyomatosis diagnosis, Lymphangioleiomyomatosis epidemiology, Lymphangioleiomyomatosis etiology, Lymphangioleiomyomatosis therapy
- Abstract
Introduction: Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease affecting mainly young women., Background: The respiratory manifestations are characterized by a progressive cystic destruction of the lung parenchyma. Extrapulmonary involvement includes benign renal tumours called angiomyolipomas and abdominal lymphatic masses called lymphangioleiomyomas. At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex). These mutations lead to the activation of the mTOR pathway, which is currently the main therapeutic target. mTOR inhibitors such as sirolimus or everolimus have shown a beneficial effect on the decline in pulmonary function and a reduction of angiomyolipoma size, but are necessary in only some patients., Perspectives: LAM cells have migratory properties mediated by the formation of new lymphatic vessels. They are also able to secrete metalloproteases, which enhance their invasiveness. Moreover, the expression of estrogen and progesterone receptors by LAM cells suggests a possible role for sex hormones in the pathogenesis of the disease., Conclusion: A better understanding of mTOR-independent mechanisms would allow the development of novel therapeutic approaches., (Copyright © 2015 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
45. [Mucosa-associated lymphoid tissue-derived (MALT) lymphoma].
- Author
-
Merveilleux du Vignaux C, Girard N, Salles G, and Cordier JF
- Subjects
- Aged, Female, Humans, Lung Neoplasms diagnostic imaging, Lymphoma, B-Cell, Marginal Zone diagnostic imaging, Radiography, Thoracic, Tomography, X-Ray Computed, Lung Neoplasms pathology, Lymphoma, B-Cell, Marginal Zone pathology
- Abstract
Pulmonary Mucosa-Associated Lymphoid Tissue (MALT)-type lymphoma is the most frequent primary pulmonary lymphoma. We report the case of a patient who presented a pulmonary MALT-type lymphoma treated with chloraminophen, with a recurrence 5 years later characterized with pulmonary lesions associated with a gastric location. This observation underlines some anatomical and clinical aspects of pulmonary MALT-type lymphoma, and leads to discuss the evolution of its physiopathological and therapeutic concepts. In particular, the contributions of positron emission tomography and molecular biology allow the analysis of possible multifocal affections of this disease., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
46. [Perioperative Outcomes in Correlation to the Learning Curve for Robotic Assisted Partial Nephrectomy: The First 109 Cases of our Clinic].
- Author
-
Cordier J, Neisius A, Thomas C, Hampel C, Thüroff JW, Brenner W, and Roos FC
- Subjects
- Aged, Blood Loss, Surgical, Carcinoma, Renal Cell pathology, Female, Glomerular Filtration Rate, Humans, Kidney Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Operative Time, Outcome Assessment, Health Care, Retrospective Studies, Statistics as Topic, Warm Ischemia, Carcinoma, Renal Cell surgery, Intraoperative Complications etiology, Kidney Neoplasms surgery, Learning Curve, Nephrectomy education, Nephrectomy methods, Postoperative Complications etiology, Robotic Surgical Procedures education, Robotic Surgical Procedures methods
- Abstract
Background: In contrast to conventional laparoscopic partial nephrectomy, the approach of robot-assisted partial nephrectomy (RAPN) shows a steep learning curve with shorter warm ischaemia times (WIT) and comparable postoperative outcomes. Therefore RAPN is considered a good minimally-invasive surgical procedure for patients presenting with a renal cell carcinoma in clinical stage cT1a. The aim of the presented study was to evaluate the perioperative outcomes of our patients after RAPN and to illustrate the learning curve based on characteristic perioperative parameters such as WIT., Material and Methods: The data of 109 patients treated by RAPN in our clinic between January 2010 and April 2015 were retrospectively analysed regarding perioperative, laboratory and oncological outcomes. Postoperative complications until 30 days after surgery were documented. We analysed the data of the largest patient population treated by a single urologist, comparing WIT, operating time, blood loss and decline of the glomerular filtration rate between the first and the second 30 consecutive cases., Results: Mean WIT was 18.4 min (SD±10.2), mean operating time was 199 min (SD±20), and mean estimated blood loss was 657 millilitres (SD±715 ml). Mean loss of GFR was reported to be 4.99 mg/dl/1.73 m (2) (SD±15.44). 83 (76%) malignant lesions were removed. 11 patients (10%) had a R1 resection, one patient had a R2 resection and in 2 cases the resection status was Rx. 22% of patients developed postoperative complications. Intraoperative complications were documented in 2 cases. According to the Clavien-Dindo Classification, 6% of patients had grade 1 and 2 complications and 13% developed grade 3 and 4 complications. WIT was significantly lower after 30 consecutive cases treated by one urologist. Regarding operating time, GFR or blood loss no significant correlation was found., Conclusion: Our data is in line with the surgical outcomes described in the literature. RAPN is a safe surgical technique with a steep learning curve. In our experience, 30 surgical cases provide a urologist with sufficient expertise to achieve good perioperative results. Weaknesses of this report include the retrospective design and insufficient documentation in some cases., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2015
- Full Text
- View/download PDF
47. [3rd French day of idiopathic pulmonary fibrosis. September 19, 2014].
- Author
-
Cottin V, Crestani B, Danel C, Debray MP, Nunes H, Poletti V, Prévost G, Vergnon JM, Wallaert B, and Cordier JF
- Subjects
- Fibroblasts, France, Humans, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis therapy, Idiopathic Pulmonary Fibrosis physiopathology, Lung physiopathology
- Published
- 2015
- Full Text
- View/download PDF
48. [Rare pulmonary diseases: from the adoption of orphan diseases to structured healthcare networks].
- Author
-
Cottin V and Cordier JF
- Subjects
- France, Health Planning Organizations trends, Humans, International Cooperation, Lung Diseases classification, Lung Diseases epidemiology, Rare Diseases classification, Rare Diseases epidemiology, Registries, Community Networks organization & administration, Lung Diseases therapy, Rare Diseases therapy
- Published
- 2014
- Full Text
- View/download PDF
49. [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies].
- Author
-
Gerfaud-Valentin M, Ahmad K, Piegay F, Fabien N, Raphanel B, Cordier JF, and Cottin V
- Subjects
- Dermatomyositis diagnosis, Dermatomyositis immunology, Electromyography, Female, Humans, Interferon-Induced Helicase, IFIH1, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial immunology, Middle Aged, Radiography, Thoracic, Autoantibodies blood, DEAD-box RNA Helicases immunology, Dermatomyositis complications, Lung Diseases, Interstitial complications
- Abstract
Introduction: Amyopathic dermatomyositis associated with anti-MDA5 autoantibodies is a rare and very recently described clinical entity., Case Report: A 58-year-old woman was admitted with subacute onset of dyspnea (NYHA class IV) associated with cough, oligoarthritis of the wrists, myalgia and intermittent fever. Examination demonstrated skin lesions with heliotrope rash, Gottron's papules, "mechanics hands", and basal inspiratory crackles on lung auscultation. Pulmonary function tests showed a restrictive ventilatory defect, with decreased carbon monoxide diffusion capacity and marked hypoxemia (PaO2 61 mmHg). The chest high-resolution computed tomography appearances were consistent with organizing pneumonia. Bronchoalveolar lavage differential cell count demonstrated 22 % neutrophils. Serum creatine kinase and electromyography were normal ; the serum ferritin level was elevated. Antinuclear antibodies were present and anti-MDA5 autoantibodies were identified. Significant improvement was obtained with systemic corticosteroids, later converted to mycophenolate mofetil as a steroid-sparing agent., Conclusion: Amyopathic dermatomyositis associated with anti-MDA5 autoantibodies shares some characteristics with those associated with anti-synthetase antibodies. Muscular involvement may be mild or absent. Early diagnosis and treatment may improve outcome., (Copyright © 2014 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.